CCR

亜型選択性的な製品

CCR製品

• All (26)
• CCR阻害剤 (7)
• CCR拮抗剤(17)
• CCR作動薬(1)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2003	Maraviroc (UK-427857)	Maravirocは、無細胞アッセイでMIP-1α、MIP-1β、およびRANTESに対するCCR5アンタゴニストであり、IC50値はそれぞれ3.3 nM、7.2 nM、および5.2 nMです。MaravirocはHIV感染症の治療に使用されます。	Nat Commun, 2025, 16(1):4591 Adv Sci (Weinh), 2025, 12(8):e2411711 J Nanobiotechnology, 2025, 23(1):696
S2907	Pirfenidone	Pirfenidoneは、TGF-β産生およびTGF-β刺激によるコラーゲン産生を阻害し、TNF-αおよびIL-1βの産生を減少させ、さらに抗線維化作用および抗炎症作用も有します。Pirfenidoneは、抗線維化活性と共にケモカイン（CCモチーフ）リガンド-2（CCL2）およびCCL12の産生を減弱させます。フェーズ3。	Biomed Pharmacother, 2025, 188:118216 Eur Respir J, 2024, 2300580 Phytomedicine, 2024, 135:156051
S3032	Bindarit (AF 2838)	Bindaritは、単球走化性タンパク質MCP-1/CCL2、MCP-3/CCL7、MCP-2/CCL8を含む炎症性ケモカインの亜族を選択的に抑制するため、独特な抗炎症活性を有する最初の合成物です。品質はNMRとHPLCで確認されています。お客様のレビュー、確認、論文をご覧ください。	Exp Mol Med, 2024, 56(2):408-421. PLoS Pathog, 2024, 20(11):e1012747 J Biol Chem, 2023, S0021-9258(23)02393-1
S8512	Cenicriviroc	Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.	Nature, 2025, 10.1038/s41586-024-08535-1 Int J Biol Sci, 2023, 19(8):2572-2587 Stem Cells, 2023, 41(6):672-683
S8220	INCB3344	INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.	Biomedicines, 2025, 13(7)1763 MedComm (2020), 2024, 5(5):e535 Commun Biol, 2024, 7(1):488
S2004	Vicriviroc Malate	Vicrivirocは、IC50が0.91 nMの強力なCCR5アンタゴニストであり、遺伝的に多様なHIV-1分離株、およびRTI、PRI、またはMDR表現型を持つ薬剤耐性ウイルスに対して広範な活性を示します。第3相。	Nature, 2013, 493(7430):51-5 Cancer Res, 2012, 72(15):3839-50 J Antimicrob Chemot, 2011, 66(4):802-12
S8501	Adaptavir (DAPTA)	Adaptavir (DAPTA, D-Ala-peptide T-amide, peptide T) is a water soluble potent, selective CCR5 antagonist which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.	Cell Death Dis, 2022, 13(5):478 Proc Natl Acad Sci U S A, 2021, 118(9)e2017282118 FEBS J, 2020, 287(11):2367-2385
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
S7604	BX471 (ZK-811752)	BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.	Nat Commun, 2025, 16(1):4581 Commun Biol, 2024, 7(1):1304
S3383	RS102895	RS 102895 is a small molecule antagonist of CCR2 with an IC50 of 360 nM.	Exp Mol Med, 2024, 56(2):408-421. Theranostics, 2022, 12(17):7351-7370
S0085	BMS-813160	BMS-813160 is a potent, well-absorbed dual CCR2 and CCR5 chemokine antagonist. BMS-813160 inhibits inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion.	Commun Biol, 2024, 7(1):1304 Mater Today (Kidlington), 2023, 62:33-50
S0129	SB-297006	SB-297006 is an antagonist of C-C chemokine receptor 3 (CCR3) that suppresses antigen-induced accumulation of T(h)2 as well as eosinophils in the lungs. SB-297006 suppressed CCL11-induced Th2 chemotaxis with IC50 of 2.5 μM.	JHEP Rep, 2023, 5(9):100805 Cell Death Dis, 2022, 13(5):478
S3479	R243	R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.	Cell Prolif, 2025, e70032.
S3494	Vicriviroc maleate	Vicriviroc maleate(SCH-417690 maleate,SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells.	Breast Cancer Res, 2021, 23(1):11
S9738	RS504393	RS504393, an extremely selective CC chemokine receptor (CCR) 2 antagonist with IC50 of 98 nM, also targets multiple receptors for inhibition of CCR2b and CCR1 receptors when administrated in higher concentration.	Mol Psychiatry, 2024, 10.1038/s41380-024-02826-9
S6555	AZD2098	AZD2098 is a potent and bioavailable CCR4 receptor antagonist with pIC50 of 7.8.	Neurooncol Adv, 2022, 4(1):vdab194
S8361	PF-4136309	PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2.	Signal Transduct Target Ther, 2025, 10(1):81
S3205	Perillaldehyde	Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.	Front Cell Dev Biol, 2025, 13:1598520
E4715	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S7538	RS-102895 Hydrochloride	RS-102895 hydrochloride (HCl) is a potent antagonist of Chemokine (C-C motif) receptor 2 (CCR2) with IC50 of 360 nM, and shows no effect on CCR1. RS-102895 hydrochloride also inhibits human α1a and α1d receptors, rat brain cortex 5-HT1a receptor in cells with IC50s of 130 nM, 320 nM, 470 nM, respectively.
E0486	C-021	C-021 is a potent CCR4 antagonist with IC50 values are 0.14 μM and 39 nM for inhibition of chemotaxis in human and mouse respectively.
S0777	Isuzinaxib (APX-115 free base)	APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
E0395	Vercirnon	Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9.
E5955New	CCR6 antagonist 1	CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
S0438	TAK-779	TAK-779(Takeda 779), a nonpeptide compound,  is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
S2907	Pirfenidone	Pirfenidoneは、TGF-β産生およびTGF-β刺激によるコラーゲン産生を阻害し、TNF-αおよびIL-1βの産生を減少させ、さらに抗線維化作用および抗炎症作用も有します。Pirfenidoneは、抗線維化活性と共にケモカイン（CCモチーフ）リガンド-2（CCL2）およびCCL12の産生を減弱させます。フェーズ3。	Biomed Pharmacother, 2025, 188:118216 Eur Respir J, 2024, 2300580 Phytomedicine, 2024, 135:156051
S3032	Bindarit (AF 2838)	Bindaritは、単球走化性タンパク質MCP-1/CCL2、MCP-3/CCL7、MCP-2/CCL8を含む炎症性ケモカインの亜族を選択的に抑制するため、独特な抗炎症活性を有する最初の合成物です。品質はNMRとHPLCで確認されています。お客様のレビュー、確認、論文をご覧ください。	Exp Mol Med, 2024, 56(2):408-421. PLoS Pathog, 2024, 20(11):e1012747 J Biol Chem, 2023, S0021-9258(23)02393-1
S8512	Cenicriviroc	Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. Cenicriviroc also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.	Nature, 2025, 10.1038/s41586-024-08535-1 Int J Biol Sci, 2023, 19(8):2572-2587 Stem Cells, 2023, 41(6):672-683
S2004	Vicriviroc Malate	Vicrivirocは、IC50が0.91 nMの強力なCCR5アンタゴニストであり、遺伝的に多様なHIV-1分離株、およびRTI、PRI、またはMDR表現型を持つ薬剤耐性ウイルスに対して広範な活性を示します。第3相。	Nature, 2013, 493(7430):51-5 Cancer Res, 2012, 72(15):3839-50 J Antimicrob Chemot, 2011, 66(4):802-12
S3479	R243	R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.	Cell Prolif, 2025, e70032.
S3205	Perillaldehyde	Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.	Front Cell Dev Biol, 2025, 13:1598520
S0777	Isuzinaxib (APX-115 free base)	APX-115 free base (Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
S2003	Maraviroc (UK-427857)	Maravirocは、無細胞アッセイでMIP-1α、MIP-1β、およびRANTESに対するCCR5アンタゴニストであり、IC50値はそれぞれ3.3 nM、7.2 nM、および5.2 nMです。MaravirocはHIV感染症の治療に使用されます。	Nat Commun, 2025, 16(1):4591 Adv Sci (Weinh), 2025, 12(8):e2411711 J Nanobiotechnology, 2025, 23(1):696
S8220	INCB3344	INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity.	Biomedicines, 2025, 13(7)1763 MedComm (2020), 2024, 5(5):e535 Commun Biol, 2024, 7(1):488
S8501	Adaptavir (DAPTA)	Adaptavir (DAPTA, D-Ala-peptide T-amide, peptide T) is a water soluble potent, selective CCR5 antagonist which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.	Cell Death Dis, 2022, 13(5):478 Proc Natl Acad Sci U S A, 2021, 118(9)e2017282118 FEBS J, 2020, 287(11):2367-2385
S7604	BX471 (ZK-811752)	BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.	Nat Commun, 2025, 16(1):4581 Commun Biol, 2024, 7(1):1304
S3383	RS102895	RS 102895 is a small molecule antagonist of CCR2 with an IC50 of 360 nM.	Exp Mol Med, 2024, 56(2):408-421. Theranostics, 2022, 12(17):7351-7370
S0085	BMS-813160	BMS-813160 is a potent, well-absorbed dual CCR2 and CCR5 chemokine antagonist. BMS-813160 inhibits inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion.	Commun Biol, 2024, 7(1):1304 Mater Today (Kidlington), 2023, 62:33-50
S0129	SB-297006	SB-297006 is an antagonist of C-C chemokine receptor 3 (CCR3) that suppresses antigen-induced accumulation of T(h)2 as well as eosinophils in the lungs. SB-297006 suppressed CCL11-induced Th2 chemotaxis with IC50 of 2.5 μM.	JHEP Rep, 2023, 5(9):100805 Cell Death Dis, 2022, 13(5):478
S3494	Vicriviroc maleate	Vicriviroc maleate(SCH-417690 maleate,SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of CCR5, with a Ki of 2.5 nM, and also inhibits HIV-1 in PBMC cells.	Breast Cancer Res, 2021, 23(1):11
S9738	RS504393	RS504393, an extremely selective CC chemokine receptor (CCR) 2 antagonist with IC50 of 98 nM, also targets multiple receptors for inhibition of CCR2b and CCR1 receptors when administrated in higher concentration.	Mol Psychiatry, 2024, 10.1038/s41380-024-02826-9
S6555	AZD2098	AZD2098 is a potent and bioavailable CCR4 receptor antagonist with pIC50 of 7.8.	Neurooncol Adv, 2022, 4(1):vdab194
S8361	PF-4136309	PF-4136309 (INCB8761, PF-04136309) is a potent, selective, and orally bioavailable CCR2 antagonist with an IC50 of 5.2 nM for human CCR2.	Signal Transduct Target Ther, 2025, 10(1):81
E4715	SB-328437	SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.
S7538	RS-102895 Hydrochloride	RS-102895 hydrochloride (HCl) is a potent antagonist of Chemokine (C-C motif) receptor 2 (CCR2) with IC50 of 360 nM, and shows no effect on CCR1. RS-102895 hydrochloride also inhibits human α1a and α1d receptors, rat brain cortex 5-HT1a receptor in cells with IC50s of 130 nM, 320 nM, 470 nM, respectively.
E0486	C-021	C-021 is a potent CCR4 antagonist with IC50 values are 0.14 μM and 39 nM for inhibition of chemotaxis in human and mouse respectively.
E0395	Vercirnon	Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9.
E5955New	CCR6 antagonist 1	CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
S0438	TAK-779	TAK-779(Takeda 779), a nonpeptide compound,  is a potent antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5. It also exhibits highly potent and selective inhibition of R5 HIV-1 replication with EC50 and EC90 of 1.2 and 5.7 nM, respectively. It also suppresses the development of the cytokine storm in the murine model of the SARS-CoV-2-related acute respiratory distress syndrome.
S8324	ZK756326 2HCl	ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.	Cancer Immunol Immunother, 2022, 10.1007/s00262-022-03196-3 J Exp Med, 2019, 216(12):2763-2777
E5955New	CCR6 antagonist 1	CCR6 antagonist 1 is a potent antagonist of CCR6 that inhibits the CCL20/CCR6 axis. It can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).

CCRシグナル伝達経路